6-chloro-6-deoxy-5'-ethylamino-2',3'-isopropylidene-5'-oxo-5'-deoxyinosine | 103201-21-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 6-chloro-6-deoxy-5'-ethylamino-2',3'-isopropylidene-5'-oxo-5'-deoxyinosine
• 英文别名: 2',3'-O,O-isopropylidene-5'-ethylamino-5'-oxo-6-chloroadenosine；(3aS,4S,6R,6aR)-6-(6-Chloro-9H-purin-9-yl)-N-ethyl-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxamide；(3aR,4R,6S,6aS)-4-(6-chloropurin-9-yl)-N-ethyl-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxole-6-carboxamide
• CAS: 103201-21-4
• 化学式: C₁₅H₁₈ClN₅O₄
• 分子量: 367.792
• InChiKey: AJHMLFKBKJLNPU-QOBXEIRBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  6-chloro-6-deoxy-5'-ethylamino-2',3'-isopropylidene-5'-oxo-5'-deoxyinosine 在 palladium on activated charcoal 盐酸 、 氢气 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 、 水 为溶剂， 反应 19.0h， 生成 N⁶-(3-aminopropyl)-5'-ethylamino-5'-oxo-5'-deoxyadenosine
  参考文献：
  名称：

  New Fluorescent Adenosine A₁-Receptor Agonists That Allow Quantification of Ligand−Receptor Interactions in Microdomains of Single Living Cells

  摘要：

  Fluorescence spectroscopy is becoming a valuable addition to the array of techniques available for scrutinizing ligand-receptor interactions in biological systems. In particular, scanning confocal microscopy and fluorescence correlation spectroscopy (FCS) allow the noninvasive imaging and quantification of these interactions in single living cells. To address the emerging need for fluorescently labeled ligands to support these technologies, we have developed a series of red-emitting agonists for the human adenosine A(1)-receptor that, collectively, are N-6-aminoalkyl derivatives of adenosine or adenosine 5'-N-ethyl carboxamide. The agonists, which incorporate the commercially available fluorophore BODIPY [630/650], retain potent and efficacious agonist activity, as demonstrated by their ability to inhibit cAMP accumulation in chinese hamster ovary cells expressing the human adenosine A(1)-receptor. Visualization and confirmation of ligand-receptor interactions at the cell membrane were accomplished using confocal microscopy, and their suitability for use in FCS was demonstrated by quantification of agonist binding in small areas of cell membrane.

  DOI：

  10.1021/jm061279i
• 作为产物：
  描述：

  2',3'-O-异丙叉肌苷 在 氯化亚砜 、 2,2,6,6-四甲基哌啶氧化物 、 碘苯二乙酸 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 氯仿 、 水 、 乙腈 为溶剂， 反应 9.5h， 生成 6-chloro-6-deoxy-5'-ethylamino-2',3'-isopropylidene-5'-oxo-5'-deoxyinosine
  参考文献：
  名称：

  New Fluorescent Adenosine A₁-Receptor Agonists That Allow Quantification of Ligand−Receptor Interactions in Microdomains of Single Living Cells

  摘要：

  Fluorescence spectroscopy is becoming a valuable addition to the array of techniques available for scrutinizing ligand-receptor interactions in biological systems. In particular, scanning confocal microscopy and fluorescence correlation spectroscopy (FCS) allow the noninvasive imaging and quantification of these interactions in single living cells. To address the emerging need for fluorescently labeled ligands to support these technologies, we have developed a series of red-emitting agonists for the human adenosine A(1)-receptor that, collectively, are N-6-aminoalkyl derivatives of adenosine or adenosine 5'-N-ethyl carboxamide. The agonists, which incorporate the commercially available fluorophore BODIPY [630/650], retain potent and efficacious agonist activity, as demonstrated by their ability to inhibit cAMP accumulation in chinese hamster ovary cells expressing the human adenosine A(1)-receptor. Visualization and confirmation of ligand-receptor interactions at the cell membrane were accomplished using confocal microscopy, and their suitability for use in FCS was demonstrated by quantification of agonist binding in small areas of cell membrane.

  DOI：

  10.1021/jm061279i

文献信息

• N6-Substituted Adenosine Receptor Agonists. Synthesis and Pharmacological Activity as Potent Antinociceptive Agents
  作者：Timur Gungor、Patrice Malabre、Jean-Marie Teulon、Francoise Camborde、Joelle Meignen、Francoise Hertz、Angela Virone-Oddos、Francois Caussade、Alix Cloarec

  DOI：10.1021/jm00051a007

  日期：1994.12

  N6-(indol-3-yl)alkyl derivatives of adenosine were synthesized. The adenosine receptor affinity and the antinociceptive activity of these compounds were assessed in binding studies and the phenylbenzoquinone-induced writhing test. Most of these analogues exhibited a potent analgesic activity without side effects. Among them, compound 3c (UP 202-32) bound to A1 (Ki = 110 nM) and A2 (Ki = 350 nM) adenosine receptors

  合成了腺苷的新型N6-（吲哚-3-基）烷基衍生物。在结合研究和苯基苯醌诱导的扭体试验中评估了这些化合物的腺苷受体亲和力和抗伤害感受活性。这些类似物中的大多数表现出有效的镇痛活性而没有副作用。其中，化合物3c（UP 202-32）以特定方式与A1（Ki = 110 nM）和A2（Ki = 350 nM）腺苷受体结合，因为它不与许多其他受体（尤其是阿片样物质结合位点）相互作用。苯基苯醌试验（ED50 = 3.3 mg / kg口服）中的抗伤害感受活性被8-环戊基茶碱拮抗，表明腺苷能机制是该化合物观察到的镇痛作用的基础。
• Fluorescent probes for adenosine receptors: Synthesis and biology of N6-dansylaminoalkyl-substituted neca derivatives
  作者：Marco Macchia、Francesca Salvetti、Silvia Barontini、Federico Calvani、Marco Gesi、Mahmoud Hamdan、Antonio Lucacchini、Antonio Pellegrini、Paola Soldam、Claudia Martini

  DOI：10.1016/s0960-894x(98)00582-4

  日期：1998.11

  New fluorescent ligands for adenosine receptors are described; these compounds were obtained by the insertion, in the N6 position of NECA (a potent adenosine agonist), of dansylaminoalkyl moieties with alkyl spacers of increasing carbon chain length (from 3 to 12). Among them, the compound with a C6 alkyl spacer proved to be the most interesting one, showing a marked selectivity for the A1 receptor

  描述了用于腺苷受体的新的荧光配体。这些化合物是通过在NECA（一种强力的腺苷激动剂）的N6位插入带有增加碳链长度（3至12）的烷基间隔基的丹磺氨基烷基部分而获得的。其中，具有C6烷基间隔基的化合物被证明是最令人感兴趣的化合物，显示出对A1受体亚型的显着选择性。此外，在荧光显微镜检测中，它被证明能够在小脑皮层的分子层水平上观察和定位该受体亚型。
• Synthesis and evaluation of adenosine derivatives as A1, A2A, A2B and A3 adenosine receptor ligands containing boron clusters as phenyl isosteres and selective A3 agonists
  作者：Katarzyna Bednarska-Szczepaniak、Adam Mieczkowski、Aleksandra Kierozalska、Dijana Pavlović Saftić、Konrad Głąbała、Tomasz Przygodzki、Lidia Stańczyk、Kamil Karolczak、Cezary Watała、Harsha Rao、Zhan-Guo Gao、Kenneth A. Jacobson、Zbigniew J. Leśnikowski

  DOI：10.1016/j.ejmech.2021.113607

  日期：2021.11

  ligands. In particular, 5′-ethylcarbamoyl-N6-(3-phenylpropyl)adenosine (18), N6-(3-phenylpropyl)-2-chloroadenosine (24) and N6-(3-phenylpropyl)adenosine (40) showed nanomolar A3 affinity (Ki 4.5, 6.4 and 7.5 nM, respectively). Among the boron cluster-containing compounds, the highest A3 affinity (Ki 206 nM) was for adenosine derivative 41 modified at C2. In the matched molecular pairs, analogs bearing boron

  合成了一系列腺苷和 2'-脱氧腺苷对，用 1,12-二碳-氯-十二硼烷簇或在相同位置用苯基修饰，并在 A 1、A 2A、A 2B处测定它们的亲和力和 A 3腺苷受体 (ARs)。虽然注意到 AR 亲和力差异，但对于大多数测试的配体，观察到优先结合 A 3 AR 而不是其他 AR 的一般趋势。具体而言，5'-乙基氨基甲酰基-N 6 -(3-苯基丙基)腺苷( 18 )、N 6 -(3-苯基丙基)-2-氯腺苷( 24 )和N 6-(3-苯基丙基)腺苷( 40 )显示出纳摩尔A 3亲和力(K i分别为4.5、6.4和7.5 nM)。在含硼簇的化合物中，最高的 A 3亲和力（K i 206 nM）是对C2 修饰的腺苷衍生物41 。在匹配的分子对中，发现带有硼簇的类似物对腺苷受体的结合亲和力低于相应的苯基类似物。然而，有趣的是，几个硼簇修饰的腺苷配体显示出比相应的苯基类似物显着更高的 A 3受体选择性：
• Discovery of Novel Adenosine Receptor Agonists That Exhibit Subtype Selectivity
  作者：Anthony Knight、Jennifer L. Hemmings、Ian Winfield、Michele Leuenberger、Eugenia Frattini、Bruno G. Frenguelli、Simon J. Dowell、Martin Lochner、Graham Ladds

  DOI：10.1021/acs.jmedchem.5b01402

  日期：2016.2.11

  A series of N6-bicyclic and N6-(2-hydroxy)cyclopentyl derivatives of adenosine were synthesized as novel A1R agonists and their A1R/A2R selectivity assessed using a simple yeast screening platform. We observed that the most selective, high potency ligands were achieved through N6-adamantyl substitution in combination with 5′-N-ethylcarboxamido or 5′-hydroxymethyl groups. In addition, we determined

  合成了一系列腺苷的N 6-双环和N 6-（2-羟基）环戊基衍生物，作为新型A 1 R激动剂，并使用简单的酵母筛选平台评估了其A 1 R / A 2 R选择性。我们观察到，通过与5'- N-乙基羧酰胺基或5'-羟甲基基团结合的N 6-金刚烷基取代获得了最具选择性，最高效的配体。此外，我们确定5'-（2-氟）硫代苯基衍生物尽管显示出与A 1 R的相互作用，但均未产生信号响应。一些选定的化合物也已在A 1上进行了测试哺乳动物细胞中的R和A 3 R揭示其中四个完全是A 1 R选择性激动剂。通过使用计算机同源性建模和配体对接，我们可以深入了解其识别和激活A 1 R的机制。我们认为，鉴于腺苷受体亚型的组织分布广泛，但信号传递曲线却相反，这些化合物可能具有治疗作用。潜在的。
• Design and Synthesis of Novel Dual-Action Compounds Targeting the Adenosine A2A Receptor and Adenosine Transporter for Neuroprotection
  作者：Jhih-Bin Chen、Eric Minwei Liu、Ting-Rong Chern、Chieh-Wen Yang、Chia-I Lin、Nai-Kuei Huang、Yun-Lian Lin、Yijuang Chern、Jung-Hsin Lin、Jim-Min Fang

  DOI：10.1002/cmdc.201100126

  日期：2011.8.1

  A novel compound, N6‐(4‐hydroxybenzyl)adenosine, isolated from Gastrodia elata and which has been shown to be a potential therapeutic agent for preventing and treating neurodegenerative disease, was found to target both the adenosine A2A receptor (A2AR) and the equilibrative nucleoside transporter 1 (ENT1). As A2AR and ENT1 are proximal in the synaptic crevice of striatum, where the mutant huntingtin

  从天麻中分离出的一种新型化合物N 6-（4-羟基苄基）腺苷已被证明是预防和治疗神经退行性疾病的潜在治疗剂，同时靶向腺苷A 2A受体（A 2A R ）和平衡核苷转运蛋白1（ENT1）。由于A 2A R和ENT1位于突变体亨廷顿聚集体所在的纹状体突触缝隙的近端，因此同时靶向这两种膜蛋白的双重作用化合物可能有益于亨廷顿舞蹈病的治疗。为了设计所需的双作用化合物，A 2A的药效团模型构建了R激动剂和ENT1抑制剂。因此，如果预测的活性在可接受的范围内，则通过腺苷的化学修饰，特别是在N 6和C 5'位置，设计和合成潜在的活性化合物。实际上，某些设计的化合物对A 2A R和ENT1均显示出显着的双重作用。两种药效基团模型在预测和测得的活性之间均显示出良好的统计相关性。与竞争性配体结合测定结果相一致，这些化合物还可以防止血清剥夺的PC12细胞凋亡，从而在神经保护中发挥关键作用，并在神经退行性疾病的治疗中具有潜在的实用性。